CDTX News and Press, Cidara Therapeutics Inc. From 10/04/18

STRIVE clinical trial successfully met all primary endpoints demonstrating the efficacy and safety of rezafungin for the treatment of invasive fungal infections Rezafungin data featured in one oral and three poster presentations showcase broad clinical utility of Cidara’s ...

WASHINGTON , Oct. 3, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, announced today that 16 of its member companies will present data from their clinical a...

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead ant...

The FDA grants Qualified Infectious Disease Product (QIDP) and Fast Track designations for Cidara Therapeutics' ( CDTX ) prophylaxis (prevention) development program for lead antifungal product candidate, rezafungin for injection. More news on: Cidara Therapeutics, Healthcare stocks news...

Rezafungin designated for the prevention of invasive fungal infections in adults undergoing bone marrow transplantation Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the U.S. Food an...